Screening using MRI for men at risk of developing prostate cancer
This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.
People with Lynch Syndrome at risk for colon cancer
This study will colect blood and stool samples to detect colorectal cancer or precancerous polyps in people with Lynch syndrome.
This study will create a system to assess an individual’s risk of breast cancer
This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.
Screening for prostate cancer using upright MRI
This study will compare the effectiveness of an upright magnetic resonance imaging (MRI) compared to prostate specific antigen (PSA) and current MRI imaging for prostate cancer screening.
Latinas with a high risk of breast cancer
This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer.
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
This study is using a new type of genetic test to measure ovarian cancer risk
This study is using a new type of genetic test to measure ovarian cancer risk in women who have inherited genetic mutations that increase their risk for ovarian cancer or women who have an ovarian cyst or other non-cancerous masses (adnexal mass).
Screening study for people at high risk for pancreatic cancer
CAPS5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer. The goal is to study biomarkers derived from images and tissue samples (blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.
People at high risk for prostate cancer due to an inherited mutation
This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.
Screening for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.
The purpose of this study is to try to find markers of early pancreatic cancer for screening for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.
The purpose of this study is to develop a test for early detection of ovarian cancer. Two patient populations are included in this study: women scheduled for surgery or testing for suspected but undiagnosed ovarian/fallopian tube cancer, and women with a BRCA1 or BRCA2 mutation who are scheduled for a risk-reducing salpingo-oophorectomy. The study will examine DNA from a washing of the uterus (womb) and proteins found in the blood to see if they can detect ovarian cancer.
Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.
The Ohio State University and FORCE want to understand if a family communication guide for people with BRCA mutations is helpful and if it’s also useful to have a video that you can text or email to family members that explains your BRCA mutation. We are currently looking for people between the ages of 18-80 who have mutation in BRCA1 or BRCA2, have an active email address, and an internet capable device like a computer, tablet, or smartphone. Participants will be asked to complete a total of 3 surveys. Participants will be randomly assigned to either receive just the communication guide or the guide plus the sharable. Each survey will take 10-15 minutes (the study could take up to 1.5 hours to complete depending on how much time you spend reviewing the study materials).
You can get more information or ask to participate in the study by sending an email to: [email protected].
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US.
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.
Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.
A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.
This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.
This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals.
The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + Screening & Early Detection
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
NCT ID: NCT04473833 (https://classic.clinicaltrials.gov/show/NCT04473833)
Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People
NCT ID: NCT04336397 (https://classic.clinicaltrials.gov/show/NCT04336397)
Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia
NCT ID: NCT04427527 (https://classic.clinicaltrials.gov/show/NCT04427527)
MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT ID: NCT05608694 (https://classic.clinicaltrials.gov/show/NCT05608694)
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
NCT ID: NCT05384535 (https://classic.clinicaltrials.gov/show/NCT05384535)
Shared Decision-making and Colorectal Cancer Screening
NCT ID: NCT04748380 (https://classic.clinicaltrials.gov/show/NCT04748380)
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
NCT ID: NCT03250078 (https://classic.clinicaltrials.gov/show/NCT03250078)
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT ID: NCT02478892 (https://classic.clinicaltrials.gov/show/NCT02478892)
Engaging Black Men in Colorectal Cancer Screening
NCT ID: NCT05980182 (https://classic.clinicaltrials.gov/show/NCT05980182)
Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening
NCT ID: NCT05665660 (https://classic.clinicaltrials.gov/show/NCT05665660)
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
NCT ID: NCT03937453 (https://classic.clinicaltrials.gov/show/NCT03937453)
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
NCT ID: NCT03699995 (https://classic.clinicaltrials.gov/show/NCT03699995)
Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study
NCT ID: NCT05838417 (https://classic.clinicaltrials.gov/show/NCT05838417)
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
NCT ID: NCT05625659 (https://classic.clinicaltrials.gov/show/NCT05625659)
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
NCT ID: NCT05694559 (https://classic.clinicaltrials.gov/show/NCT05694559)
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
NCT ID: NCT05298605 (https://classic.clinicaltrials.gov/show/NCT05298605)
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
NCT ID: NCT05667532 (https://classic.clinicaltrials.gov/show/NCT05667532)
Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT ID: NCT05129605 (https://classic.clinicaltrials.gov/show/NCT05129605)
Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
NCT ID: NCT04890054 (https://classic.clinicaltrials.gov/show/NCT04890054)
Upright MRI for Prostate Cancer Screening
NCT ID: NCT03474913 (https://classic.clinicaltrials.gov/show/NCT03474913)
A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care
NCT ID: NCT03407417 (https://classic.clinicaltrials.gov/show/NCT03407417)
Early Detection of Breast Cancer
NCT ID: NCT06043661 (https://classic.clinicaltrials.gov/show/NCT06043661)
Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer
NCT ID: NCT05055843 (https://classic.clinicaltrials.gov/show/NCT05055843)
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT ID: NCT04030507 (https://classic.clinicaltrials.gov/show/NCT04030507)
The PRIME-CRC Trial to Promote CRC Screening in Rural Communities
NCT ID: NCT04313114 (https://classic.clinicaltrials.gov/show/NCT04313114)
The Purpose of This Study is to Determine the Frequency of Colorectal Cancer in Male and Female Endurance Athletes Between the Ages of 35 and 50
NCT ID: NCT05419531 (https://classic.clinicaltrials.gov/show/NCT05419531)
Colonoscopy Screening: Setting Epic Follow-up Times
NCT ID: NCT05631873 (https://classic.clinicaltrials.gov/show/NCT05631873)
Novel Thermal Imaging Technique for Breast Screening
NCT ID: NCT05650086 (https://classic.clinicaltrials.gov/show/NCT05650086)
Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans
NCT ID: NCT03640208 (https://classic.clinicaltrials.gov/show/NCT03640208)
BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
NCT ID: NCT05051631 (https://classic.clinicaltrials.gov/show/NCT05051631)
Improving Cancer Screening and Follow-up in Community Health Centers
NCT ID: NCT05756725 (https://classic.clinicaltrials.gov/show/NCT05756725)
Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study
NCT ID: NCT04671498 (https://classic.clinicaltrials.gov/show/NCT04671498)
Empowering Latinas to Obtain Guideline Concordant Screenings
NCT ID: NCT05841355 (https://classic.clinicaltrials.gov/show/NCT05841355)
Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography
NCT ID: NCT04348123 (https://classic.clinicaltrials.gov/show/NCT04348123)
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
NCT ID: NCT05524428 (https://classic.clinicaltrials.gov/show/NCT05524428)
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
NCT ID: NCT04904757 (https://classic.clinicaltrials.gov/show/NCT04904757)
A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer
NCT ID: NCT05408260 (https://classic.clinicaltrials.gov/show/NCT05408260)
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT ID: NCT03729115 (https://classic.clinicaltrials.gov/show/NCT03729115)
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
NCT ID: NCT04854304 (https://classic.clinicaltrials.gov/show/NCT04854304)
Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention
NCT ID: NCT04192071 (https://classic.clinicaltrials.gov/show/NCT04192071)
Virtual Colonoscopy Using Omnipaque as a Contrast Agent
NCT ID: NCT04582500 (https://classic.clinicaltrials.gov/show/NCT04582500)
Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening
NCT ID: NCT05975736 (https://classic.clinicaltrials.gov/show/NCT05975736)
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
NCT ID: NCT04085510 (https://classic.clinicaltrials.gov/show/NCT04085510)
Mammogram Mail- and Phone-based Interventions
NCT ID: NCT05853848 (https://classic.clinicaltrials.gov/show/NCT05853848)
Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images
NCT ID: NCT05960188 (https://classic.clinicaltrials.gov/show/NCT05960188)
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
NCT ID: NCT05483283 (https://classic.clinicaltrials.gov/show/NCT05483283)
Autoantibodies in Breast Cancer Detection
NCT ID: NCT03623945 (https://classic.clinicaltrials.gov/show/NCT03623945)
A Sociolinguistic-enabled Web Application to Develop Precision Health Intervention for African Americans
NCT ID: NCT04705363 (https://classic.clinicaltrials.gov/show/NCT04705363)
Southeast Asian Women's Health Project
NCT ID: NCT04086771 (https://classic.clinicaltrials.gov/show/NCT04086771)
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NCT ID: NCT05678322 (https://classic.clinicaltrials.gov/show/NCT05678322)
Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
NCT ID: NCT05127096 (https://classic.clinicaltrials.gov/show/NCT05127096)
Colorectal Cancer Screening in Cystic Fibrosis
NCT ID: NCT05362344 (https://classic.clinicaltrials.gov/show/NCT05362344)
Informed Choice - Compass
NCT ID: NCT05246839 (https://classic.clinicaltrials.gov/show/NCT05246839)
African Cancer Genome: GMD
NCT ID: NCT05754658 (https://classic.clinicaltrials.gov/show/NCT05754658)
Magnetic Resonance Imaging of Breast Cancer
NCT ID: NCT01035112 (https://classic.clinicaltrials.gov/show/NCT01035112)
Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://classic.clinicaltrials.gov/show/NCT03568630)
Enhancing Cancer Prevention and Control Pathways-Native Health Initiative
NCT ID: NCT04259762 (https://classic.clinicaltrials.gov/show/NCT04259762)
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients, CORAL Study
NCT ID: NCT05410977 (https://classic.clinicaltrials.gov/show/NCT05410977)
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
NCT ID: NCT04341129 (https://classic.clinicaltrials.gov/show/NCT04341129)
Nipple Aspirate Fluid in Detecting Breast Cancer
NCT ID: NCT03715959 (https://classic.clinicaltrials.gov/show/NCT03715959)
Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
NCT ID: NCT05056818 (https://classic.clinicaltrials.gov/show/NCT05056818)
Longitudinal Performance of Epi proColon
NCT ID: NCT03218423 (https://classic.clinicaltrials.gov/show/NCT03218423)
The Effect of IBD Flares on Serum PSA
NCT ID: NCT03558048 (https://classic.clinicaltrials.gov/show/NCT03558048)
New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)
NCT ID: NCT05188586 (https://classic.clinicaltrials.gov/show/NCT05188586)
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
NCT ID: NCT05471128 (https://classic.clinicaltrials.gov/show/NCT05471128)
The Genomic Medicine at VA Study
NCT ID: NCT04331535 (https://classic.clinicaltrials.gov/show/NCT04331535)
Pancreatic Cancer Early Detection Program
NCT ID: NCT02206360 (https://classic.clinicaltrials.gov/show/NCT02206360)
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT ID: NCT04825834 (https://classic.clinicaltrials.gov/show/NCT04825834)
Early Detection of Breast Cancer in Women With Suspicious Mammograms
NCT ID: NCT03147430 (https://classic.clinicaltrials.gov/show/NCT03147430)
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
NCT ID: NCT00539162 (https://classic.clinicaltrials.gov/show/NCT00539162)
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
NCT ID: NCT00579514 (https://classic.clinicaltrials.gov/show/NCT00579514)
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT ID: NCT00843375 (https://classic.clinicaltrials.gov/show/NCT00843375)
Predicting Chronic Pain Following Breast Surgery
NCT ID: NCT04967352 (https://classic.clinicaltrials.gov/show/NCT04967352)
Collection of Samples USOPTIVAL Study
NCT ID: NCT04792684 (https://classic.clinicaltrials.gov/show/NCT04792684)
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
NCT ID: NCT05732623 (https://classic.clinicaltrials.gov/show/NCT05732623)
Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases
NCT ID: NCT04973007 (https://classic.clinicaltrials.gov/show/NCT04973007)
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT ID: NCT03789162 (https://classic.clinicaltrials.gov/show/NCT03789162)
Evaluation of Transperineal Biopsy Under Local Anesthesia
NCT ID: NCT04843566 (https://classic.clinicaltrials.gov/show/NCT04843566)
Transperineal vs. Transrectal MRI-targeted Prostate Biopsy
NCT ID: NCT04815876 (https://classic.clinicaltrials.gov/show/NCT04815876)
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.